Joshua Bliesath

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

Megan J. Bywater, Gretchen Poortinga, Elaine Sanij et al. · Cancer Cell · 2012 · 552 citations · Full text

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Molecular and Cellular Biochemistry · 2011 · 151 citations

Medicine, Cancer Growth, Immune Checkpoint Inhibitor +8

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

Adam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino et al. · Molecular Cancer Therapeutics · 2012 · 98 citations

Dna-targeted Anticancer Drugs, Cancer Biology, Dna Repair Response +19

Structural and Biochemical Characterization of the Therapeutic Anabaena variabilis Phenylalanine Ammonia Lyase

Lin Wang, Alejandra Gámez, Holly Archer et al. · Journal of Molecular Biology · 2008 · 90 citations · Full text

Biochemistry, Phenylalanine Ammonia Lyase, Therapeutic Anabaena +2

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor

Mustapha Haddach, Jerome Michaux, Michael K. Schwaebe et al. · ACS Medicinal Chemistry Letters · 2011 · 84 citations · Full text

Pim Kinases, Pharmacotherapy, A Potent +18